http://orcid.org/0000-0003-0021-4861
References
- Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta‐analysis. Rev Med Virol. 2019;29:e2034.
- Lee KG, Teo SH, Lim C, et al. Severe gastrointestinal cytomegalovirus disease in two patients with renal vasculitis after immunosuppression. CN. 2016;86:154–161.
- Lim CC, Tung YT, Tan BH, et al. Epidemiology and risk factors for cytomegalovirus infection in glomerular diseases treated with immunosuppressive therapy. Nephrology. 2017;23:676–681.
- Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–1097.
- Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–360.
- Celebi ZK, Calayoglu R, Yalci AK, et al. Cytomegalovirus disease in patients with glomerular diseases treated by immunosuppressive treatment. Int Urol Nephrol. 2014;46:2357–2360.
- Yates M, Watts R, Bajema I, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–1594.
- Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ. 1973;49:103–106.
- Bataille S, Moal V, Gaudart J, et al. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression. Transpl Infect Dis. 2010;12:480–488.
- Hanaoka R, Kurasawa K, Maezawa R, et al. Reactivation of cytomegalovirus predicts poor prognosis in patients on intensive immunosuppressive treatment for collagen-vascular diseases. Mod Rheumatol. 2012;22:438–445.
- Tsai WP, Chen MH, Lee MH, et al. Cytomegalovirus infection causes morbidity and mortality in patients with autoimmune diseases, particularly systemic lupus: in a Chinese population in Taiwan. Rheumatol Int. 2012;32:2901–2908.
- Takizawa Y, Inokuma S, Tanaka Y, et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology. 2008;47:1373–1378.
- Owers DS, Webster AC, Strippoli GF, et al. Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. The Cochrane Library. 2013.
- Koval CE. Prevention and treatment of cytomegalovirus infections in solid organ transplant recipients. Infect Dis Clin. 2018;32:581–597.
- Matsumoto K, Shigemi A, Ikawa K, et al. Risk factors for ganciclovir-induced thrombocytopenia and leukopenia. Biol Pharm Bull. 2015;38:235–238.
- Tan BH. CMV prophylaxis—to do or not to do, that is the question. Nephrol Dialysis Transplant. 2006;21:1757–1761.
- Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063–4071.
- Mori T, Kameda H, Ogawa H, et al. Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy. J Rheumatol. 2004;31:1349–1351.
- Jang E-Y, Park SY, Lee EJ, et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis. 2009;48:e121–e124.
- Kliem V, Fricke L, Wollbrink T, et al. Improvement in long‐term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8:975–983.